<DOC>
	<DOCNO>NCT00943059</DOCNO>
	<brief_summary>Accumulation lipid skeletal cardiac muscle associate insulin resistance diabetic cardiomyopathy . In skeletal muscle , lipotoxic damage suggest lead dysfunction mitochondrion . It remain unknown whether lipotoxicity lead mitochondrial dysfunction heart well , , whether also lead cardiomyopathy ( failure heart ) . Although show lipid lower agent improve insulin sensitivity , effect lower free fatty acid cardiac skeletal muscle mitochondrial function remain unknown . In study investigator want investigate whether lower cardiac muscular lipid content improve mitochondrial cellular function type 2 diabetic patient . To end , type 2 diabetic patient body mass index ( BMI ) -matched control include blinded cross-over design , subject receive lipid lowering agent ( Acipimox ) placebo 2 week random order . During treatment , diabetes medication stop . Baseline measurement perform prior study treatment assess cardiac muscular lipid accumulation , cardiac function , mitochondrial function insulin sensitivity .</brief_summary>
	<brief_title>Cross-over Study Effect Lipid Lowering Acipimox Cardiac Skeletal Muscle Mitochondrial Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Acipimox</mesh_term>
	<criteria>Male postmenopausal female Age 4070 year Obese ( BMI &gt; 30 kg/m2 ) , noninsulin dependent type 2 diabetic patient BMI match control subject without diabetes . Generally healthy specifically know cardiovascular disease , dyslipidemia , gastric ulcer ( contraind . Acipimox ) , affect study parameter . Must sulphonylurea ( SU ) derivate metformin therapy least six month constant dose least two month , dietary treatment least six month Wellcontrolled diabetes : HbA1c &lt; 8 % . Control subject must plasma glucose low 6,1 mmol/L . Stable dietary habit ( weight loss/gain &gt; 3 kg last 6 month ) Known cardiovascular disease , dyslipidemia , hepatic renal failure gastric ulcer . Insulin dependent Diabetic patient . Use lipid lowering agent , except Statins , affect triglyceride level ( exception Lipitor ) . Use Thiazolidines ( glitazone/rosiglitazone/pioglitazone/troglitazone ) Use anticoagulant ( thrombocyteaggregation inhibitor ) Aberrant ECG ( sign ischemia cardiac failure arrythmia 's ) Weight gain/loss &gt; 3 kg last 6 month . Hb &lt; 7,3 woman , &lt; 7,8 men . Contraindications MRI scan : Electronic implant pacemaker neurostimulator Ironcontaining corpus aliena eye brain Some hearing aid artificial ( heart ) valve contraindicate MRS Claustrophobia Subjects , want inform unexpected medical finding , wish physician inform , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Mitochondrial function</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>lipid lowering</keyword>
	<keyword>triglyceride</keyword>
	<keyword>Acipimox</keyword>
</DOC>